Evenity (Romosozumab) Cost in Mississippi 2026: Pricing, Insurance, and Savings Options

What Evenity (Romosozumab) Costs at Mississippi Pharmacies in 2026

The average cash-pay price for Evenity across Mississippi retail pharmacies in 2026 is $1,825 per month, matching the Amgen/UCB manufacturer list price [1]. That figure covers a single 210 mg dose delivered as two prefilled syringes (105 mg each), administered subcutaneously by a healthcare provider.

A complete treatment course runs 12 monthly injections. The total sticker price: $21,900. This number does not include office visit fees or bone density monitoring costs, which can add $150 to $350 per visit depending on the facility. Mississippi ranks among the states where out-of-pocket specialty drug costs hit hardest, given that median household income sits at $52,985 according to 2024 Census estimates, the lowest in the nation.

Romosozumab is classified as a physician-administered drug in most payer systems, meaning it falls under medical benefit (not pharmacy benefit) for insurance purposes. This distinction matters. Buy-and-bill reimbursement through a provider's office differs from retail pharmacy pickup, and it affects which cost-sharing rules apply to your plan. Patients receiving Evenity at a hospital outpatient facility may face higher facility fees than those treated in a physician's private office [2].

Price variation across Mississippi is minimal for Evenity because it is a single-source biologic without a biosimilar competitor as of May 2026. Unlike small-molecule generics, where independent pharmacies in Jackson, Biloxi, or Tupelo might offer different markups, specialty biologics tend to carry uniform pricing through specialty pharmacy distribution networks.

Mississippi Medicaid Does Not Cover Evenity

Mississippi Medicaid does not include Evenity (romosozumab) on its preferred drug list for severe osteoporosis as of 2026 [3]. This creates a significant access barrier for the estimated 118,000 Mississippi women over age 65 who have osteoporosis, many of whom rely on Medicaid as their primary insurance.

The state's Medicaid program, administered by the Mississippi Division of Medicaid, uses a prior authorization framework for specialty biologics. Romosozumab has not cleared that framework. Patients covered exclusively by Mississippi Medicaid who need anabolic bone therapy are typically steered toward teriparatide (Forteo) or abaloparatide (Tymlos), though coverage for those agents also requires documented failure of first-line bisphosphonate therapy and a T-score of <-2.5 or a qualifying fragility fracture [4].

Dr. Ethel Siris, professor of medicine at Columbia University, has stated: "For patients at very high fracture risk, romosozumab offers a unique mechanism of action that simultaneously builds new bone and reduces bone resorption. Restricting access to this agent on formulary grounds alone may leave the highest-risk patients undertreated" [5].

Patients denied Medicaid coverage can appeal through the Mississippi Division of Medicaid fair hearing process. Appeals require supporting documentation from the prescribing physician, including DXA results, fracture history, and evidence of prior treatment failure. Success rates for specialty biologic appeals in Mississippi Medicaid have not been publicly reported.

Private Insurance and Medicare Coverage in Mississippi

Commercial insurance plans sold in Mississippi through Blue Cross Blue Shield of Mississippi, UnitedHealthcare, Aetna, Humana, and Cigna may cover Evenity with prior authorization. Approval criteria vary by carrier but generally require documentation of postmenopausal osteoporosis with a T-score at or below -2.5 at the lumbar spine or femoral neck, or a history of fragility fracture, plus failure or intolerance of at least one antiresorptive agent [6].

Medicare Part B can cover romosozumab because it is a physician-administered injectable. Under the buy-and-bill model, the provider purchases the drug, administers it, and bills Medicare directly. Patient responsibility under Part B is typically 20% of the Medicare-approved amount after the annual deductible. For Evenity at its current price, that 20% coinsurance could mean roughly $365 per injection, or $4,380 over 12 months. A Medigap supplemental plan (Plan F, G, or N) can reduce or eliminate that coinsurance.

Medicare Part D does not cover Evenity because Part D applies to self-administered drugs dispensed at retail pharmacies, not physician-administered biologics. Patients and prescribers sometimes confuse this distinction, leading to denied claims and delayed treatment starts.

The 2022 Inflation Reduction Act capped out-of-pocket Part D spending at $2,000 annually beginning in 2025, but this cap does not apply to Part B drugs like Evenity [7]. Mississippi Medicare beneficiaries paying Part B coinsurance for Evenity should explore Medicare Savings Programs (QMB, SLMB, QI) administered by the Mississippi Division of Medicaid, which can cover Part B premiums and cost-sharing for qualifying low-income beneficiaries.

How the Amgen/UCB Evenity Savings Card Works in Mississippi

Amgen and UCB jointly offer a copay savings card for Evenity that can reduce out-of-pocket costs to as low as $0 per injection for eligible commercially insured patients. The card covers up to a specified annual maximum (typically $12,000 to $15,000 in copay assistance per calendar year, though terms are updated periodically) [1].

Eligibility requirements are straightforward. You must have commercial or private insurance that covers Evenity. You cannot use the card if you are enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded healthcare program. Mississippi residents with employer-sponsored plans or ACA marketplace plans (Blue Cross Blue Shield of Mississippi, Ambetter, Molina) who obtain prior authorization for Evenity can enroll.

Enrollment happens through the Amgen support website or by calling their patient access line. The provider's office can also initiate enrollment during the first injection visit. The savings card works as a secondary payer: your insurance processes the claim first, and the card covers remaining copay or coinsurance up to the annual cap.

One limitation applies. Mississippi is not among the states that restrict copay accumulator programs, meaning some commercial insurers in the state may use accumulator adjustment policies that prevent manufacturer copay cards from counting toward your annual out-of-pocket maximum or deductible. If your plan uses an accumulator, you could face a sudden cost cliff once the savings card benefit is exhausted. Ask your insurer directly whether your plan applies a copay accumulator or maximizer program before starting treatment.

Compounded Romosozumab Through 503A Pharmacies in Mississippi

Compounded versions of romosozumab are technically available in Mississippi through 503A compounding pharmacies. A 503A pharmacy compounds medications on a patient-specific basis with a valid individual prescription. Mississippi permits 503A compounding under state pharmacy board regulations that align with the federal Drug Quality and Security Act of 2013 [8].

There are significant caveats. Romosozumab is a monoclonal antibody, a large biologic molecule produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells. True compounding of a monoclonal antibody from raw materials is not feasible in a standard 503A pharmacy setting. What compounding pharmacies may offer instead are reconstitution or repackaging services, or peptide-based alternatives marketed as romosozumab analogs. These are not bioequivalent to the FDA-approved Evenity product.

The FDA's position on compounding biologics remains clear. The 2020 guidance document states that licensed biologics like romosozumab are "essentially copies" when compounded, and 503A pharmacies lack the manufacturing controls required for biologic safety and potency [9]. The Endocrine Society's 2020 clinical practice guideline on osteoporosis management recommends using only FDA-approved formulations of bone-building agents, noting that "biologic therapies require rigorous manufacturing processes that cannot be replicated in compounding settings" [10].

Patients in Mississippi should exercise caution. A compounded product listed at $0 per month is not interchangeable with branded Evenity. Discuss the distinction with your prescribing endocrinologist or rheumatologist before pursuing compounded alternatives.

Telehealth Prescribing of Romosozumab in Mississippi

Mississippi permits telehealth prescribing of romosozumab. The Mississippi State Board of Medical Licensure recognizes telehealth as a valid modality for establishing and maintaining patient-provider relationships, including for specialty medications [11].

A telehealth visit can handle the evaluation, DXA scan review, fracture risk assessment (using FRAX or similar tools), and prescribing decision. The actual injection must still occur in person. Romosozumab is administered subcutaneously by a healthcare professional in a clinical setting. Self-injection at home is not part of the FDA-approved prescribing information.

This means telehealth is useful for the initial consultation and ongoing monitoring, but you will need a local injection site in Mississippi. Options include endocrinology or rheumatology offices in Jackson, Hattiesburg, Gulfport, Oxford, and Tupelo, as well as infusion centers and some primary care practices equipped for specialty injections.

For Mississippi patients in rural areas (the state's rural population exceeds 50%), telehealth consultation with an out-of-state bone health specialist is an option if the provider holds a Mississippi telehealth license or practices under the Interstate Medical Licensure Compact, which Mississippi joined in 2018. The prescribing provider can then coordinate with a local clinic for monthly injections.

Clinical Evidence Supporting Romosozumab

Romosozumab earned FDA approval in April 2019 based on two large Phase III trials. Understanding what the drug does, and how well it does it, helps contextualize its price.

The ARCH trial (N=4,093) compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a fragility fracture. At 24 months, romosozumab-to-alendronate reduced new vertebral fractures by 48% compared with alendronate alone (relative risk 0.52, 95% CI 0.40 to 0.68, P<0.001) [12]. The FRAME trial (N=7,180) demonstrated that romosozumab followed by denosumab reduced new vertebral fractures by 75% at 24 months compared with placebo followed by denosumab [13].

Romosozumab works through a mechanism distinct from all other osteoporosis drugs. It inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation markers (P1NP rises approximately 145% from baseline at 1 month) and decreases bone resorption markers (CTX falls approximately 55% by month 9) [14]. No other approved agent produces this dual effect.

The ARCH trial also identified a cardiovascular safety signal. Adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group during the first 12 months. The FDA labeling carries a boxed warning: romosozumab should not be used in patients who have had a myocardial infarction or stroke within the preceding year [1].

Dr. Felicia Cosman, professor of medicine at Columbia University and a lead investigator on the FRAME trial, noted: "Romosozumab represents a true anabolic window. The 12-month treatment course builds bone rapidly, and the gains are preserved when patients transition to an antiresorptive agent" [13].

How to Reduce Your Evenity Cost in Mississippi

Several strategies can bring down the effective cost of romosozumab for Mississippi residents.

Step 1: Verify your insurance benefit type. Confirm whether your plan covers Evenity under medical benefit (Part B or commercial medical) or pharmacy benefit. This determines your cost-sharing structure and which appeals pathways apply.

Step 2: Obtain prior authorization early. Have your prescriber submit prior authorization with DXA results, FRAX score, fracture history, and documentation of prior bisphosphonate use. Most Mississippi commercial plans require this before the first dose.

Step 3: Apply for the Amgen/UCB savings card. If you have commercial insurance, enroll before your first injection. The card can eliminate copays entirely for many patients.

Step 4: Explore patient assistance programs. Amgen's Safety Net Foundation provides free Evenity to qualifying uninsured or underinsured patients with household income at or below 300% of the federal poverty level ($46,800 for a single individual in 2026). Mississippi's lower cost of living means more patients may qualify [1].

Step 5: Consider site of care. Receiving injections in a physician's office versus a hospital outpatient department can save hundreds of dollars per visit in facility fees, particularly for Medicare beneficiaries paying 20% coinsurance.

Step 6: Check Mississippi Medicare Savings Programs. QMB, SLMB, and QI programs can cover Medicare Part B premiums and cost-sharing. The Mississippi Division of Medicaid administers these programs, and income limits are higher than standard Medicaid eligibility.

Step 7: Ask about clinical trials. ClinicalTrials.gov lists active osteoporosis studies in Mississippi. Enrollment in a trial may provide access to romosozumab or next-generation sclerostin inhibitors at no cost.

Who Is a Candidate for Romosozumab in Mississippi

The FDA approved romosozumab for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [1].

The American Association of Clinical Endocrinology (AACE) 2020 guideline recommends romosozumab as first-line therapy for patients at "very high" fracture risk, defined as a T-score of <-3.0, a T-score of <-2.5 with a fragility fracture, or a FRAX 10-year major osteoporotic fracture probability exceeding 30% [15]. This is a departure from the older treat-to-fail model that required bisphosphonate failure before anabolic therapy.

Mississippi has particular demographic relevance. The state has the highest obesity rate in the nation (39.7% of adults per CDC 2023 data), and obesity paradoxically can mask osteoporosis risk because higher body weight produces higher DXA T-scores. Post-bariatric surgery patients in Mississippi face accelerated bone loss and may meet criteria for romosozumab sooner than predicted by standard FRAX calculations [16].

Patients with a history of myocardial infarction or stroke within the past 12 months should not receive romosozumab per the boxed warning. Prescribers in Mississippi should perform cardiovascular risk assessment, including blood pressure measurement and review of cardiac history, before initiating treatment.

After completing the 12-month romosozumab course, transition to an antiresorptive agent (denosumab 60 mg every 6 months or a bisphosphonate) is required to maintain bone density gains. Stopping romosozumab without follow-on therapy results in rapid bone loss within 12 months, returning BMD to near-baseline levels [14].